Advanced search    

Search: authors:"Alessandra Lugaresi"

25 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Natalizumab treatment reduces L-selectin (CD62L) in CD4 + T cells

Background The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients. CD62L is involved in rolling and transmigration of leukocyte cells. A correlation between CD62LCD4 + T cells low expression and progressive multifocal leukoencephalopathy (PML) development has been suggested in multiple sclerosis (MS) patients...

Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory

Background The Multiple Sclerosis Quality of Life-54 (MSQOL-54, 52 items grouped in 12 subscales plus two single items) is the most used MS specific health related quality of life inventory. Objective To develop a shortened version of the MSQOL-54. Methods MSQOL-54 dimensionality and metric properties were investigated by confirmatory factor analysis (CFA) and Rasch modelling...

Patient Expression of Emotions and Neurologist Responses in First Multiple Sclerosis Consultations

Background Anxiety and depression are common in people with multiple sclerosis (MS), but data on emotional communication during MS consultations are lacking. We assessed patient expressions of emotion and neurologist responses during first-ever MS consultations using the Verona Coding Definitions of Emotional Sequences (VR-CoDES). Methods We applied VR-CoDES to recordings...

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis Alessandra Lugaresi,1 Maria di Ioia,1 Daniela Travaglini,1 Erika Pietrolongo,1 Eugenio Pucci,2 Marco

The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study

Novartis. Gioacchino Tedeschi has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc., Merck Serono, BayerSchering. Alessandra Lugaresi declared receipt of grants and

Improving patient–physician dialog: commentary on the results of the MS Choices survey

manuscript and for collating input from all authors (AP), and for English editing and assistance with preparation for submission (JT). Disclosure Alessandra Lugaresi has been an advisory board member for

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

Pozzilli 4 Giancarlo Comi 3 Alessandra Lugaresi Renato Turrini Debora Raimondi Antonio Uccelli 0 Giovanni Luigi Mancardi 0 on behalf of the EAP Investigators 0 Department of Neuroscience, Rehabilitation

Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial

Background Preliminary evidence suggests that palliative care may be useful for people with severe multiple sclerosis (MS). The aim of this study is to determine the effectiveness of a home-based palliative approach (HPA) for people with severe MS and their carers. Methods/design This is a single-blind randomized controlled trial with a nested qualitative study. Seventy-five...

Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention

Background Few data on services for people with severe multiple sclerosis (MS) are available. The Palliative Network for Severely Affected Adults with MS in Italy (PeNSAMI) developed a home palliative care program for MS patients and carers, preceded by a literature review and qualitative study (here reported). Objective To identify unmet needs of people with severe MS living at...

Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments

Objective To assess decision-making in multiple sclerosis (MS) from third observer and patient perspectives. Method Audio recordings of first-ever consultations with a participating physician (88 outpatients, 10 physicians) at four tertiary MS care clinics in Italy, were rated by a third observer using the Observing Patient Involvement in Shared Decision Making (OPTION) and by...

A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients

Giovanni Bosco Zimatore 8 Erika Pietrolongo 3 Alessandra Lugaresi 3 Lorena Pippolo 10 Marco Roscio 10 Angelo Ghezzi 10 Debora Castellano 11 Sergio Stecchi 11 Maria Pia Amato 0 0 Department of NEUROFARBA

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

Virginia Devonshire Txomin Arbizu Bjrn Borre Michael Lang Alessandra Lugaresi Barry Singer Elisabetta Verdun di Cantogno Peter Cornelisse Background: Multiple sclerosis (MS) currently requires long ... ); Germany: Wolfgang Elias (Yasmin Brendel), Michael Lang (Urte Kuckenhorn), Said Masri (Nadine Sebald), Gerd Reifschneider (Heidi Klber*); Italy: Alessandra Lugaresi (Giovanna De Luca), Enrico Millefiorini

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

Background Achieving good adherence to self-injected treatments for multiple sclerosis can be difficult. Injection devices may help to overcome some of the injection-related barriers to adherence that can be experienced by patients. We sought to assess short-term adherence to, and tolerability of, interferon (IFN) β-1a administered via electronic autoinjection device in patients...

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

Achieving good adherence to self-injected treatments for multiple sclerosis can be difficult. Injection devices may help to overcome some of the injection-related barriers to adherence that can be experienced by patients. We sought to assess short-term adherence to, and tolerability of, interferon (IFN) β-1a administered via electronic autoinjection device in patients with...

The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population

Background BICAMS (Brief International Cognitive Assessment for Multiple Sclerosis) has been recently developed as brief, practical and universal assessment tool for cognitive impairment in MS subjects. It includes the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory Test�Revised (BVMT-R) . In this study we aimed...

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study

Paolicelli 4 8 Maria Trojano 4 8 Maria Giovanna Marrosu 4 7 Francesco Patti 4 6 Gian Luigi Mancardi 4 5 Claudio Solaro 4 10 Rocco Totaro 4 9 Maria Rosaria Tola 3 4 Giovanna De Luca 4 12 Alessandra Lugaresi 4

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study

Most of Multiple Sclerosis (MS) patients undergo disease modifying drug (DMD) therapy at childbearing age. The objective of this prospective, collaborative study, was to assess outcomes of pregnancies fathered by MS patients undergoing DMD. Structured interviews on pregnancies fathered by MS patients gathered in the Italian Pregnancy Dataset were collected; pregnancies were...

Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients

Valentina Durastanti 0 4 Alessandra Lugaresi 2 Placido Bramanti 1 Mariapia Amato 8 Paolo Bellantonio 7 Giovanna De Luca 2 Orietta Picconi 6 Roberta Fantozzi 5 Laura Locatelli 10 Annalisa Solda' 9

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

Background Multiple Sclerosis is more common in women than men and females have more relapses than men. In a large international cohort we have evaluated the effect of gender on disability accumulation and disease progression to determine if male MS patients have a worse clinical outcome than females. Methods Using the MSBase Registry, data from 15,826 MS patients from 25...